Evidence map›Paper›PMID 23590571›Full record

Trial reportEuropean journal of clinical investigation2013

Baseline comorbidities in a skin cancer prevention trial in Bangladesh.

Maria Argos, Mahfuzar Rahman, Faruque Parvez, James Dignam, Tariqul Islam, Iftekhar Quasem, Samar K Hore, Ahmed T Haider, Zahid Hossain, Tazul I Patwary and 13 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 2 countries.

Maria ArgosDepartment of Health Studies, The University of Chicago, Chicago, IL 60637, USA.
Mahfuzar Rahman
Faruque Parvez
James Dignam
Tariqul Islam
Iftekhar Quasem
Samar K Hore
Ahmed T Haider
Zahid Hossain
Tazul I Patwary
Muhammad Rakibuz-Zaman
Golam Sarwar
Paul La Porte
Judith Harjes
Kristen Anton
Muhammad G Kibriya
Farzana Jasmine
Rashed Khan
Mohammed Kamal
Christopher R Shea
Muhammad Yunus
John A Baron
Habibul Ahsan
University of Chicago · USUniversity of Chicago Research Bangladesh · BDInternational Centre for Diarrhoeal Disease Research · BDBangabandhu Sheikh Mujib Medical University · BDColumbia University · USDartmouth College · USShaheed Suhrawardy Medical College · BD

Funding

Training CoreP42ES010349 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NAVAS-ACIEN, ANA · 2000 to 2020
$53.6M
Chemoprevention of arsenic-induced skin cancerR01CA107431 · NCI · UNIVERSITY OF CHICAGO · PI AHSAN, HABIBUL · 2005 to 2014
$17.3M
NCI NIH HHS R01 CA107431NIEHS NIH HHS P42 ES010349
6 · The paper itself

Abstract

backgroundEpidemiologic research suggests that increased cancer risk due to chronic arsenic exposure persists for several decades even after the exposure has terminated. Observational studies suggest that antioxidants exert a protective effect on arsenical skin lesions and cancers among those chronically exposed to arsenic through drinking water. This study reports on the design, methods and baseline analyses from the Bangladesh Vitamin E and Selenium Trial (BEST), a population-based chemoprevention study conducted among adults in Bangladesh with visible arsenic toxicity. MATERIALS AND

methodsBangladesh Vitamin E and Selenium Trial is a 2 × 2 full factorial, double-blind, randomized controlled trial of 7000 adults having manifest arsenical skin lesions evaluating the efficacy of 6-year supplementation with alpha-tocopherol (100 mg daily) and L-selenomethionine (200 μg daily) for the prevention of nonmelanoma skin cancer.

resultsIn cross-sectional analyses, we observed significant associations of skin lesion severity with male gender (female prevalence odds ratio (POR) = 0.87; 95% CI = 0.79-0.96), older age (aged 36-45 years, POR = 1.27; 95% CI = 1.13-1.42; aged 46-55 years, POR = 1.44; 95% CI = 1.27-1.64 and aged 56-65 years, POR = 1.50; 95% CI = 1.26-1.78 compared with aged 25-35 years), hypertension (POR = 1.29; 95% CI = 1.08-1.55), diabetes (POR = 2.13; 95% CI = 1.32-3.46), asthma (POR = 1.55; 95% CI = 1.03-2.32) and peptic ulcer disease (POR = 1.20; 95% CI = 1.07-1.35).

conclusionsWe report novel associations between arsenical skin lesions with several common chronic diseases. With the rapidly increasing burden of preventable cancers in developing countries, efficient and feasible chemoprevention study designs and approaches, such as employed in BEST, may prove both timely and potentially beneficial in conceiving cancer chemoprevention trials in Bangladesh and beyond.

Indexed as

AdultAgedalpha-TocopherolAnticarcinogenic AgentsAntioxidantsArsenic PoisoningBangladeshDouble-Blind MethodFemaleHumansMaleMiddle AgedSelenomethionineSkin Neoplasmsalpha-TocopherolAnticarcinogenic AgentsAntioxidantsSelenomethionine

Identifiers

PMID23590571
PMCPMC3953314
OpenAlexW2025207912

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.